Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foundation Medicine Seeks "Go-To" Companion Diagnostic Status For Sequencing Test

This article was originally published in The Pink Sheet Daily

Executive Summary

Foundation says its test service will transition next-generation sequencing from the research bench to routine clinical practice, with the ultimate goal of supplanting the need for individual gene mutation tests to drive oncology drug therapy decisions.

You may also be interested in...



Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan

Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.

Roche Could Repeat Genentech Success With Foundation Medicine Partnership

Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.

Deals Of The Week: Mersana/Endo, Nuron/Akshaya, Array BioPharma/Foundation Medicine

The Domain Associates/Rusnano tie-up looks new on the surface, but is driven by a familiar imperative – the need to find new funding streams for biotechs still working to build up their exit value.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel